Cardiovascular benefit from PCSK9 drug unaltered by diabetes

Presence of diabetes had no bearing on cardiovascular risk reduction with the PCSK9 inhibitor evolocumab (Repatha), researchers report in a study published in theLancet Diabetes and Endocrinology.Medpage Today
Source: Society for Endocrinology - Category: Endocrinology Source Type: news